Vera Therapeutics (VERA) Cash from Restructuring (2020 - 2021)
Vera Therapeutics (VERA) reported Cash from Restructuring of $124000.0 for Q4 2021, down 94.69% on a YoY basis from $2.3 million in Q4 2020, and down 0.8% quarter-over-quarter from $125000.0 in Q3 2021.
Vera Therapeutics (VERA) Cash from Restructuring (2020 - 2021) Analysis & Trends
Vera Therapeutics has reported Cash from Restructuring for 2 years, with the latest figure at $124000.0 in Q4 2021.
- For the quarter ending Q4 2021, Cash from Restructuring fell 94.69% year-over-year to $124000.0; the trailing twelve-month figure through Sep 2022 stood at $124000.0 (down 96.14% YoY), and the FY2021 full-year result was $999000.0, down 58.77% from the prior year.
- Cash from Restructuring for Q4 2021 stood at $124000.0, down from $125000.0 in the prior quarter.
- The five-year high for Cash from Restructuring was $2.3 million in Q4 2020, with the low at $29000.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Vera Therapeutics | 2.51 Bn | 1.91 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 124,000.00 |
| Sep 30, 2021 | 125,000.00 |
| Jun 30, 2021 | 160,000.00 |
| Mar 31, 2021 | 590,000.00 |
| Dec 31, 2020 | 2.34 Mn |
| Sep 30, 2020 | 30,000.00 |
| Jun 30, 2020 | 29,000.00 |
| Mar 31, 2020 | 29,000.00 |